
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.
EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...





